NO20022008L - Fremgangsmåte og preparater for oral administrering av taxaner til humane pasienter - Google Patents

Fremgangsmåte og preparater for oral administrering av taxaner til humane pasienter

Info

Publication number
NO20022008L
NO20022008L NO20022008A NO20022008A NO20022008L NO 20022008 L NO20022008 L NO 20022008L NO 20022008 A NO20022008 A NO 20022008A NO 20022008 A NO20022008 A NO 20022008A NO 20022008 L NO20022008 L NO 20022008L
Authority
NO
Norway
Prior art keywords
taxanes
preparations
methods
oral administration
human patients
Prior art date
Application number
NO20022008A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022008D0 (no
Inventor
Samuel Brodor
Kenneth Duchin
Sami Selim
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of NO20022008D0 publication Critical patent/NO20022008D0/no
Publication of NO20022008L publication Critical patent/NO20022008L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20022008A 1999-10-27 2002-04-26 Fremgangsmåte og preparater for oral administrering av taxaner til humane pasienter NO20022008L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16231099P 1999-10-27 1999-10-27
PCT/US2000/029633 WO2001030448A1 (en) 1999-10-27 2000-10-27 Method and compositions for administering taxanes orally to human patients

Publications (2)

Publication Number Publication Date
NO20022008D0 NO20022008D0 (no) 2002-04-26
NO20022008L true NO20022008L (no) 2002-06-19

Family

ID=22585092

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022008A NO20022008L (no) 1999-10-27 2002-04-26 Fremgangsmåte og preparater for oral administrering av taxaner til humane pasienter

Country Status (18)

Country Link
EP (1) EP1225956A1 (cs)
JP (1) JP2003512443A (cs)
KR (1) KR20030019296A (cs)
CN (1) CN1450923A (cs)
AU (1) AU1104201A (cs)
BR (1) BR0015149A (cs)
CA (1) CA2389583A1 (cs)
CO (1) CO5251425A1 (cs)
CZ (1) CZ20021484A3 (cs)
HU (1) HUP0203303A3 (cs)
IL (1) IL149360A0 (cs)
MX (1) MXPA02004164A (cs)
NO (1) NO20022008L (cs)
PL (1) PL354777A1 (cs)
RU (1) RU2002113659A (cs)
SK (1) SK5822002A3 (cs)
WO (1) WO2001030448A1 (cs)
ZA (1) ZA200203358B (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
AU2002239282A1 (en) 2000-11-28 2002-06-11 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
JP2006514698A (ja) * 2002-10-30 2006-05-11 スフェリックス， インコーポレイテッド ナノ粒子生物活性物質
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
AR050043A1 (es) * 2004-08-03 2006-09-20 Novartis Ag Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares
CN101513395B (zh) * 2008-02-20 2011-01-12 单宝华 紫杉醇类双层软胶囊口服制剂药物
CA2781527C (en) 2009-09-23 2017-10-24 Indu Javeri Methods for the preparation of liposomes
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
CA2798180A1 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
JO3737B1 (ar) * 2015-07-21 2021-01-31 Athenex Therapeutics Ltd تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان
CN112670147A (zh) * 2019-10-15 2021-04-16 北京烁科中科信电子装备有限公司 一种利用多磁极磁棒间距控制的自动调节剂量均一性的方法
EP4059497A1 (en) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
CA3212816A1 (en) * 2021-03-17 2022-09-22 Dompe' Farmaceutici Spa C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
EP0822815A4 (en) * 1996-01-31 1998-04-01 Bristol Myers Squibb Co PROCESS FOR MAKING ORAL-LIKE TAXANES ACTIVE FROM THE PHARMACEUTICAL VIEW
CA2258556A1 (en) * 1996-06-17 1997-12-24 Julian Stanley Kroin Drug resistance and multidrug resistance modulators
UA74767C2 (en) * 1997-05-27 2006-02-15 Baker Norton Pharma Method and composition for oral use of taxanes in patients
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU756752B2 (en) * 1998-04-01 2003-01-23 Skyepharma Canada Inc. Anticancer compositions
EP1178786A4 (en) * 1999-05-21 2006-03-01 American Bioscience Inc PHARMACOLOGICALLY ACTIVE PROTEIN STABILIZING AGENTS; METHODS OF MANUFACTURE AND METHODS OF USE

Also Published As

Publication number Publication date
HUP0203303A3 (en) 2005-01-28
HUP0203303A2 (hu) 2003-02-28
KR20030019296A (ko) 2003-03-06
MXPA02004164A (es) 2002-10-17
EP1225956A1 (en) 2002-07-31
WO2001030448A1 (en) 2001-05-03
AU1104201A (en) 2001-05-08
ZA200203358B (en) 2003-04-29
BR0015149A (pt) 2002-10-29
NO20022008D0 (no) 2002-04-26
CA2389583A1 (en) 2001-05-03
JP2003512443A (ja) 2003-04-02
PL354777A1 (en) 2004-02-23
CO5251425A1 (es) 2003-02-28
RU2002113659A (ru) 2004-01-27
SK5822002A3 (en) 2003-01-09
IL149360A0 (en) 2002-11-10
CN1450923A (zh) 2003-10-22
CZ20021484A3 (cs) 2003-12-17

Similar Documents

Publication Publication Date Title
NO20022008L (no) Fremgangsmåte og preparater for oral administrering av taxaner til humane pasienter
NO20015888L (no) Implanterbart gelpreparat og fremgangsmåter for fremstilling derav
NO20003051D0 (no) Metode for administrering av AspB28-humant insulin
IS6892A (is) Lyfjasamsetningar, skammtaform og aðferðir til aðgefa epóþílon um munn
NO996433D0 (no) Nye formuleringer av legemidler, fremgangsmåter for fremstilling derav og fremgangsmåter for anvendelse derav
CY2007033I2 (el) Μεθοδος και φαρμακευτικο σκευασμα για την αντιμετωπιση της αντιστασης στα αντιυπερτασικα φαρμακα και για σχετικες παθησεις
IS5500A (is) Lyfjablöndur til öftrunar og meðferðar mýlildi ogtengdum sjúkdómum
HUE040046T2 (hu) Gyógyszerészeti készítmények és hatóanyagok beadására szolgáló eljárások
EE04417B1 (et) Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm, selle valmistamise meetod ja kasutamine
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
PL377931A1 (pl) Farmaceutyczne preparaty donosowe oraz sposoby ich stosowania
ATE293971T1 (de) Pharmazeutische kombinationen enthaltend tegaserod und omeprazole und ihre verwendung zur behandlung gastrointestinaler krankheiten
EP1421185A4 (en) FAST TIE TEMPERATURE PRESSURE STERILIZATION AND VACCINE MANUFACTURING
NO995812L (no) Metode og sammensetninger for administrering av taxaner oralt til pasienter
DK1210119T3 (da) Farmaceutiske sammensætninger til oral og topisk administrering
NO20004405D0 (no) Farmasøytisk sammensetning for profylakse og terapi av sykdommer forbundet med okulær-fundus-vev cytopati
EP1575993A4 (en) METHOD FOR TREATING PATIENTS AND IDENTIFYING THERAPEUTICS
IS2199B (is) Svæfandi ß-karbólín afleiður, aðferð til framleiðslu þeirra og notkun þeirra sem læknislyf
NO20014812L (no) Fremgangsmate for tilveiebringelse av kosmetisk/medisinsk terapi
IS2331B (is) 2-arýlimínó-2,3-díhýdróþíasólafleiður, aðferðir til að framleiða þær og meðferðarfræðileg notkun þeirra
NO20030794D0 (no) Fremgangsmåter for legemiddelavlevering til hepatocytter og behandling av flavivirida-infeksjoner
EP1569601A4 (en) MORINGA ESTERS AND COSMETIC AND PHARMACEUTICAL PREPARATIONS AND METHOD FOR THE PRODUCTION THEREOF
NO20024823L (no) Medisinske preparater inneholdende camptothecin-derivat og pH regulerende middel
NO20000376D0 (no) Transdermalt terapeutisk system for frigiving av virkestoff gjennom huden inn i en organisme og fremgangsmåte for påfoering på huden
PT1206253E (pt) Preparacoes farmaceuticas solidas contendo nanossois de quitosano e metodo de preparacao

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application